tradmap

MDXG Financials Mimedx Group, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 11.0% per year over the past 5 years.
  • Operating margin has expanded, at 15.3% in the latest year.

Financial health

  • The company holds more cash ($166M) than total debt ($18M).
  • Total debt has grown slower than revenue (-18.5% vs 11.0% per year).
  • Operating income covered interest expense 36× in the latest year.
  • Total debt is 0.2× EBITDA.
Revenue & net income
-$49M $185M $419M $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-20% 35% 90% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-12543% 10157% 32856% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
-$19M $3M $25M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $83M $166M 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$60M $7M $74M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $419M $49M 82.6% 15.3% 18.9% 14.2% $18M $166M
2024 $349M $42M 82.8% 16.9% 22.0% 16.1% $19M $104M
2023 $321M $58M 83.0% 11.5% 40.8% 24.4% $25M $50M $82M
2022 $268M -$30M 82.0% -5.5% 167.9% -17.6% -$19M $50M $66M
2021 $242M -$10M 83.6% -2.9% -12542.7% -5.5% -$5M $50M $87M
2020 $248M -$49M 84.2% -18.3% 32856.0% -24.4% $50M $96M
2019 $299M -$26M 85.6% -7.1% -74.4% -15.3% $73M $69M
2018 $359M -$30M 89.9% -1.1% -60.4% -24.4% $0 $45M
2017 $321M $65M 89.0% 14.4% 87.7% 53.4% $27M
2016 $222M $390000 86.0% 0.4% 0.8% 0.3% $30M
2015 $29M 84.8% 21.7% $26M
2014 $6M 7.0% 5.7% $47M
2013 -$4M -5.6% -4.9% $0 $44M
2012 -$8M -38.3% -21.8% $4M $7M
2011 -$10M -85.7% -37.6% $4M $4M

Valuation over time

How the market has priced MDXG against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 16.5 33.1 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 2.4 4.8 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is MDXG growing its revenue and profit?

Over the past 5 years, Mimedx Group, Inc.'s revenue has grown 11.0% per year. These are computed facts, not advice.

How much debt does MDXG have?

As of FY2025, Mimedx Group, Inc. reported $18M of total debt against $166M of cash; operating income covered interest expense 36×.

What is MDXG's profit margin?

In FY2025, gross margin was 82.6%, operating margin 15.3%, and net margin 11.6%.

What is MDXG's P/E ratio?

As of Sep '26, Mimedx Group, Inc. traded at a price-to-earnings ratio of about 13.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.